Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Breast cancer sourcebook / / edited by Karen Bellenir
| Breast cancer sourcebook / / edited by Karen Bellenir |
| Edizione | [3rd ed.] |
| Pubbl/distr/stampa | Detroit, MI, : Omnigraphics, c2009 |
| Descrizione fisica | 1 online resource (xix, 633 pages) : illustrations, maps |
| Disciplina | 616.99/449 |
| Collana | Health reference series |
| Soggetto topico |
Breast - Cancer
Breast - Cancer - Diagnosis Breast - Cancer - Treatment Breast - Cancer - Research |
| ISBN |
1-282-26344-7
9786612263446 0-7808-1099-6 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
""Table of Contents""; ""Preface""; ""Part One - Breast Health""; ""Chapter 1 - Anatomy of the Breast""; ""Chapter 2 - Breast Self-Examination""; ""Chapter 3 - Understanding Breast Changes""; ""Chapter 4 - What Are Benign Breast Conditions?""; ""Chapter 5 - Breast Lumps: What You Should Know""; ""Part Two - Breast Cancer Fundamentals""; ""Chapter 6 - What You Need to Know about Breast Cancer""; ""Chapter 7 - Inflammatory Breast Cancer""; ""Chapter 8 - Paget Disease of the Nipple""; ""Chapter 9 - Male Breast Cancer""; ""Chapter 10 - Breast Cancer Statistics""
""Chapter 11 - Breast Cancer in Minority Populations""""11.1 - Breast Cancer Incidence and Mortality by Race and Ethnicity""; ""11.2 - Breast Cancer Health Disparities: Questions and Answers""; ""11.3 - Estimating Breast Cancer Risk in African Americans""; ""11.4 - Younger Black Women Develop a More Lethal Type of Breast Cancer""; ""11.5 - Hispanic Breast Cancer Differences Persist with Equal Access to Care""; ""11.6 - Triple-Negative Breast Cancer Disproportionately Affects African American and Hispanic Women""; ""Chapter 12 - Pregnancy and Breastfeeding May Influence Breast Cancer Risk"" ""Chapter 13 - Medications and Breast Cancer Risk""""13.1 - Antibiotics and Breast Cancer Risk""; ""13.2 - Oral Contraceptives and Breast Cancer Risk""; ""13.3 - Decrease in Breast Cancer Rates Related to Reduction in Use of Hormone Replacement Therapy""; ""13.4 - Hormone Replacement Therapy and Breast Cancer Relapse""; ""13.5 - Cancer Risk Persists after Ending Hormone Therapy""; ""Chapter 14 - Environmental Factors and Breast Cancer Risk""; ""Chapter 15 - Genes and Breast Cancer Risk""; ""15.1 - Genes Related to Breast Cancer"" ""15.2 - Small Variations in Estrogen-Receptor Genes Can Determine Risk of Developing Breast Cancer""""15.3 - CHEK2 Gene Carries Risk of Breast Cancer""; ""15.4 - Genetic Testing for Cancer Risk""; ""Chapter 16 - Can Breast Cancer Be Prevented?""; ""Chapter 17 - Preventive Mastectomy: Questions, Answers, and Concerns""; ""Part Three - Breast Cancer Screening and Diagnosis""; ""Chapter 18 - Screening for Breast Cancer""; ""Chapter 19 - Understanding Mammography""; ""19.1 - What You Should Know about Screening and Diagnostic Mammograms""; ""19.2 - Digital vs. Film Mammography"" ""19.3 - Computer-Aided Detection Reduces Accuracy of Mammograms""""19.4 - Annual Mammography Reduces Mortality in Older Breast Cancer Survivors""; ""19.5 - Recent Drop in Mammography Rates Causes Concern""; ""19.6 Breast Implant Adverse Events during Mammography""; ""Chapter 20 - Using Magnetic Resonance Imaging (MRI) to Detect Breast Cancer""; ""Chapter 21 - Evaluating a Breast Lump""; ""Chapter 22 - Breast Biopsies""; ""Chapter 23 - Sentinel Lymph Node Biopsy""; ""Chapter 24 - Questions and Answers about Your Pathology Report""; ""Chapter 25 - Hormone Receptor Status Testing"" ""Chapter 26 - Human Epidermal Growth Factor Receptor (HER2/neu) Testing"" |
| Record Nr. | UNINA-9910828714503321 |
| Detroit, MI, : Omnigraphics, c2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast cancer updates / / Selim Sözen, Seyfi Emir, editors
| Breast cancer updates / / Selim Sözen, Seyfi Emir, editors |
| Pubbl/distr/stampa | London : , : IntechOpen, , 2023 |
| Descrizione fisica | 1 Online-Ressource (306 pages) |
| Disciplina | 616.99449 |
| Soggetto topico | Breast - Cancer - Treatment |
| ISBN | 1-80355-931-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1. Obesity and Breast Cancer -- By Abdullah Sisik, Hasan Erdem, Muhammed Said Dalkiliç, Mehmet Gençtürk, Merih Yilmaz and Selim Sözen -- 2. Epidemiology of Breast Cancer in Sub-Saharan Africa -- By Philip Adewale Adeoye -- 3. Breast Cancer and Pregnancy: Epidemiology, Phenotypes, Presentation during Pregnancy, and Therapeutic Approaches -- By Massimiliano Berretta, Oreste Claudio Buonomo, Gianluca Vanni and Bianca Arianna Facchini -- 4. Breast Cancer in Brazil: Social Conditions and Access to Health Care -- By Mônica de Castro Maia Senna, Thaislayne Nunes de Oliveira and Debora Louzada Carvalho -- 5. Breast Cancer, Gender, and Body Experience - A Qualitative Study in Argentina on the Transit of the Illness, Femininity, and Sexuality at Stake -- By Leila Martina Passerino -- 6. Breast Cancer in the Elderly -- By Agnieszka Jagiello-Gruszfeld and Agnieszka Mlodzinska -- 7. Management of the Triple Negative Locally Advanced Breast Cancer -- By Amir Iqbal Memon, Ikram Din Ujjan and Aisha Masroor Bhatti -- 8. Inter-Relationship of Ki-67 and Triple-Negative Breast Cancer -- By Ankit Jain, Vijayakumar Chellappa and Kadambari Dharanipragada -- 9. Bcl-2 Immunoexpression in Invasive Ductal Carcinoma and Its Evaluative Correlation with Molecular Sub-Types and BR-Grade and TNM Stage -- By Poornima Pandey and Arvind Bhake -- 10. Correlation between Ultrasound Findings and Molecular Subtypes of Breast Cancer -- By Eman Soliman Metwally, Rahma Mohammed Abed Alghazal and Ah Haggaa Ali -- 11. A Short Communication: Non-acid Nucleic Blood Multi-Factors Panels for Primary Breast Cancer Detection - A Systematic Review and Network Meta-Analysis -- By Vahid Raja, Ziba Farajzadegan, Marjan Mansourian, Khojaste Ghasemi, Mohammad Sadegh Aboutalebi, Rasool Nouri and Fariborz Mokarian -- 12. Membrane-Bound Complement Regulatory Proteins in Breast Cancer: Are They Best Therapeutic Targets? -- By Sofia Álvarez-Lorenzo, Rebeca Elizabeth Montalvo-Castro, Jeannie Jiménez-López, María Adriana Medina-Mondragón and Nohemí Salinas-Jazmín -- 13. Minimally Invasive Surgery in Breast Reconstruction: The Past and Future -- By Elizabeth A. Bailey and Sarah N. Bishop -- 14. Solutions in Breast Reconstruction -- By Perçin Karakol, Mert Noyan Dabak and Ömer Büyükkaya -- 15. Breast Reconstructive Options -- By Benjamin Liliav and Luis Torres-Strauss -- 16. Oncoplastic Breast Conservation: A Standard of Care in Modern Breast Cancer Surgical Management -- By Ana Car Peterko -- 17. Physiotherapeutic Management in Breast Cancer Patients -- By Margit Eidenberger -- 18. Antibody Drug Conjugates -- By Farah Raheem and Vishal Shah. |
| Record Nr. | UNINA-9910727281803321 |
| London : , : IntechOpen, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood
| Breast cancer, from bench to personalized medicine / / edited by Saima Shakil Malik and Nosheen Masood |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (534 pages) |
| Disciplina | 616.9449 |
| Soggetto topico |
Breast - Cancer - Treatment
Breast - Cancer Càncer de mama Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-19-0197-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Acknowledgment -- Contents -- About the Editors -- Part I: Overview of Breast Cancer -- 1: Epidemiology and Risk Factors of Breast Cancer -- 1.1 Introduction -- 1.1.1 Invasive Ductal Carcinoma -- 1.1.2 Invasive Lobular Carcinoma -- 1.2 Morphological and Molecular Classification of Breast Tumors -- 1.2.1 Morphological Classification -- 1.2.2 Molecular Classification -- 1.3 Global Distribution and Epidemiology of Breast Cancer -- 1.4 Risk Factors Influencing Tumor Behavior -- 1.4.1 Genetic Factors -- 1.4.1.1 BRCA -- 1.4.1.2 PALB2 -- 1.4.1.3 TP53 -- 1.4.1.4 ATM -- 1.4.1.5 CDH1 -- 1.4.1.6 CHEK2 -- 1.4.1.7 STK11 -- 1.4.1.8 NF1 -- 1.4.1.9 NBN -- 1.4.2 Epigenetic Factors -- 1.4.3 Demographic Factors -- 1.4.4 Blood Group -- 1.4.5 Reproductive Factors -- 1.4.5.1 Menarche Age -- 1.4.5.2 Full-Term Pregnancy -- 1.4.5.3 Abortion -- 1.4.5.4 Menstrual Cycle -- 1.4.6 Endocrine Factors -- 1.4.6.1 Contraceptive Methods -- 1.4.6.2 Ovulation-Stimulating Drugs -- 1.4.6.3 Postmenopausal Hormone Therapy -- 1.4.7 Family History -- 1.4.8 Breast Density and Lactation -- 1.4.9 Environmental Factors -- 1.4.9.1 Environmental Factors -- 1.4.9.2 Radiation -- 1.4.9.3 Exposure to Various Chemicals -- 1.4.9.4 Lifestyle Factors -- 1.4.9.5 Body Mass Index (BMI) -- 1.4.9.6 Hyperglycemia -- 1.4.9.7 Alcohol Consumption -- 1.4.9.8 Smoking -- 1.4.9.9 Diet -- 1.4.9.10 Sleep Patterns -- 1.4.9.11 Caffeine -- 1.4.9.12 Physical Activity -- 1.4.9.13 Vitamin D -- 1.4.9.14 Socioeconomic Status -- 1.5 Prevention Strategies and Treatments for Breast Cancer -- 1.6 Conclusion -- References -- 2: Histopathological Characteristics: Breast Cancer Subtypes Depending on Receptor Status, Clinical and Pathological Staging o... -- 2.1 Introduction -- 2.2 Histological Classification of Breast Cancer -- 2.2.1 Invasive Breast Cancer -- 2.2.1.1 Invasive Ductal Carcinoma.
2.2.1.1.1 Medullary Breast Carcinoma -- Histological Organization of Medullary Breast Carcinoma -- 2.2.1.1.2 Metaplastic Carcinoma -- Histological Organization of Metaplastic Breast Cancer -- 2.2.1.1.3 Adenoid Cystic Carcinoma -- Histological Organization of Adenoid Cystic Carcinoma of Breast -- 2.2.1.1.4 Mucinous Carcinoma -- Histological Organization of Mucinous Carcinoma -- 2.2.1.1.5 Tubular Carcinoma -- Histological Organization of Tubular Carcinoma -- 2.2.1.1.6 Carcinoma with Papillary Morphology -- Histological Organization of Papillary Carcinoma -- 2.2.1.1.7 Apocrine Carcinoma (Androgen-Receptor Positive and Estrogen-Receptor Negative) -- Histological Organization of Apocrine Carcinoma -- 2.2.1.1.8 Neuroendocrine Carcinoma -- Histological Organization of Neuroendocrine Carcinoma -- 2.2.1.2 Invasive Lobular Carcinoma -- 2.2.1.2.1 Histological Organization of Invasive Lobular Carcinoma. -- 2.3 Conclusion -- References -- 3: Relationship of Breast Cancer with Other Hormone-Sensitive Cancers -- 3.1 Introduction -- 3.2 Role of Hormones in Breast Cancer -- 3.2.1 Tumor-Promoting Effects of Estrogen -- 3.2.2 Tumor-Promoting Effects of Progesterone -- 3.2.3 Melatonin and Hormone-Dependent Breast Cancer -- 3.2.4 Hormonal Contraception and Breast Cancer -- 3.2.5 Menopause Hormone Therapy and Breast Cancer -- 3.3 Relation Between Breast Cancer and Other Hormones Related to Cancer -- 3.3.1 Different Hormones Sensitive Cancers -- 3.3.2 Breast Cancer and Ovarian Cancer -- 3.3.3 Breast Cancer and Endometrial Cancer -- 3.4 Biomarkers in Breast and OHRC -- 3.4.1 N1-Acetylspermidine as a Chemical Biomarker -- 3.4.2 Mucin-1, Urokinase-Type Plasminogen Activator as Protein Biomarker -- 3.4.3 Ki-67 as a Prophetic Marker in Breast Cancer -- 3.4.4 HER2 as a Prophetic Marker in Breast Cancer -- 3.5 Genetics Behind Hormonal Breast Cancer. 3.5.1 BRCA1 and BRCA2 Gene Mutation -- 3.5.2 High Menace Gene Mutations in PALB2, PTEN, and TP53 Genes -- 3.5.3 Moderate Menace Gene Mutations in ATM and cdh1genes -- 3.5.4 Less Risk Gene Mutations in CHEK2, NBN, NF1, and STK11 Genes -- 3.6 Conclusion -- References -- 4: Cancer Care and Psychosocial Needs -- 4.1 Introduction -- 4.1.1 Death and Survival Rates -- 4.1.2 Risk Factors -- 4.1.2.1 Inherent Risk Factors -- 4.1.2.2 Environmental Factors -- 4.1.2.3 Behavioral Risk Factors -- 4.2 Living with Cancer -- 4.2.1 Adjusting to Diagnosis and Treatment -- 4.3 Cancer Induced Stressor -- 4.3.1 Psychosocial Stressors -- 4.3.2 Consequences of Stressors -- 4.4 Psychosocial Aspects of Cancer -- 4.4.1 Social Support -- 4.4.2 Communication -- 4.4.3 Management of Psychosocial Aspects -- 4.4.4 Psychotherapy with Cancer Patients -- References -- Part II: Cell and Molecular Biology of Breast Cancer (Diagnosis and Prognosis) -- 5: Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer -- 5.1 Introduction -- 5.1.1 Genes Related to Breast Cancer -- 5.2 Importance of Detection of BRCA Mutations -- 5.3 Pathology of BRCA1 and BRCA2 Associated Breast Cancers -- 5.3.1 BRCA-1 and BRCA-2 Probability Models -- 5.3.2 BOADICEA Model -- 5.3.3 BRCAPRO Model -- 5.3.4 Couch Model -- 5.3.5 Manchester Model -- 5.3.6 Myriad Model -- 5.3.7 Tyrer-Cuzick Model -- 5.4 Implication of BRCA1/2 in Hereditarily Onset of Breast Cancer -- 5.5 Advantages and Disadvantages of Screening and Genetic Testing -- 5.5.1 Advantages of Screening and Genetic Testing -- 5.5.2 Disadvantages of Screening and Genetic Testing -- 5.6 Future Perspective -- References -- 6: Early-Stage Progression of Breast Cancer -- 6.1 Early-Stage Progression of Breast Cancer -- 6.2 Epigenetics in Breast Cancer Progression -- 6.3 Molecular Classification of Breast Cancer. 6.4 ERPT Positive Group: Luminal Type -- 6.5 ERNT Negative Group -- 6.5.1 HER2 Enriched Subclass -- 6.5.2 Breast Like -- 6.5.3 Basal Like -- 6.6 Progression of Breast Cancer and Role of Cell Specific Polarity Proteins -- 6.7 Role of High and Low Penetrance Genes -- 6.8 High Penetrance Breast Cancer Genes -- 6.9 BRCA1 and BRCA2 -- 6.9.1 PALB2 -- 6.9.2 TP53 -- 6.9.3 PTEN -- 6.9.4 STK11 -- 6.9.5 CDH1 -- 6.10 Low Penetrance Breast Cancer Genes -- References -- 7: Noninvasive Biomarkers: Emerging Trends in Early Detection of Breast Cancer -- 7.1 Introduction -- 7.2 Types of Noninvasive Biomarkers -- 7.2.1 Blood-Based Biomarker -- 7.2.1.1 Circulating Carcinoma Proteins -- 7.2.1.2 Circulating Tumor Cells -- 7.2.1.3 Circulating Cell-Free Tumor DNA -- 7.2.1.4 Circulating miRNAs -- 7.2.1.5 Extracellular Vesicles -- 7.2.1.6 Other Blood-Based Biomarkers -- 7.2.2 Non-blood-Based Biomarkers -- 7.2.2.1 Tears -- 7.2.2.2 Breath -- 7.2.2.3 Nipple Aspirate Fluid -- 7.2.2.4 Apocrine Sweat -- 7.2.2.5 Urine -- 7.3 Biomarkers Involved in Cancer Progression/Proliferation -- 7.3.1 circRNAs -- 7.3.2 miRNAs -- 7.4 Biomarkers Involved in Cancer Metastasis -- 7.4.1 miRNAs -- 7.4.2 Chemokines -- 7.5 Biomarkers Involved in Cancer Drug Resistance -- 7.5.1 circRNA -- 7.5.2 miRNA -- 7.6 Progress of Breast Cancer Biomarker Research: Limitations, Challenges, and Future Perspective -- 7.7 Conclusion -- References -- 8: Epigenetics Involvement in Breast Cancer -- 8.1 Introduction -- 8.2 Epigenetics and Breast Cancer -- 8.3 Epigenetic Mechanisms in the Breast Cancer -- 8.3.1 DNA Methylation -- 8.3.2 Histone Modifications -- 8.3.3 Non-coding RNAs (ncRNAs) -- 8.4 Epigenetics as a Diagnostic Tool for Breast Cancer -- 8.4.1 DNA Methylation as Potential Diagnostic Biomarker -- 8.4.2 Non-coding RNAs as Potential Diagnostic Biomarker -- 8.5 Epigenetics as Predictive Biomarkers. 8.5.1 DNA Methylation as Predictive Markers -- 8.5.2 Histone Modifications as Predictive Biomarkers -- 8.5.3 ncRNAs as Potential Predictive Biomarkers -- 8.6 Epigenetics as Prognostic Markers in Breast Cancer -- 8.6.1 DNA Methylation as a Prognostic Biomarker -- 8.6.2 Histone Modification as a Biomarker -- 8.6.3 Non-coding RNAs as Prognostic Biomarkers -- 8.7 Epigenetics Modifications as Therapeutic Target -- 8.8 Conclusion -- References -- 9: Role of Fibrinolytic Mechanisms in Breast Cancer Diagnosis, Prognosis, and Treatment -- 9.1 Introduction: Fibrinolysis and Fibrinolytic System -- 9.2 Breast Cancer Etiology -- 9.3 Pathologies Associated with Fibrinolytic System in Breast Cancer -- 9.3.1 Breast Cancer Progression and Role of Hemostatic Function -- 9.4 Components of Fibrinolytic System -- 9.4.1 Plasminogen and Plasmin -- 9.4.2 Thrombin -- 9.4.3 Tissue Factors -- 9.5 Fibrinolytic System as Diagnostic Target -- 9.5.1 Prognostic Biomarkers -- 9.5.2 Diagnostic Biomarkers -- 9.6 Fibrinolytic System as Therapeutic Target -- 9.6.1 Inhibitors of Coagulation -- 9.6.2 Transcriptional Repression -- 9.6.3 Small Molecules and Epigenetic Agents -- 9.6.4 Toxin Conjugates -- 9.6.5 Antibodies -- 9.6.6 Peptide Inhibitors -- 9.6.7 Natural and Chemical Products -- 9.6.8 Aptamers -- 9.7 Conclusion and Future Directions -- References -- 10: MicroRNAs and Noncoding RNAs as Gene Regulators and Potential Therapeutic Agents -- 10.1 Introduction -- 10.2 Biogenesis of miRNA -- 10.2.1 Canonical Pathway Aimed at miRNA Biogenesis -- 10.2.2 Non-canonical Pathway Aimed at miRNA Biogenesis -- 10.3 MicroRNAs as a Gene Regulator -- 10.3.1 MicroRNAs Mediated Gene Silencing -- 10.3.2 MicroRNA-Mediated Translational Activation -- 10.4 Significance of Noncoding RNA into the Breast Cancer -- 10.4.1 miRNA and Breast Cancer -- 10.4.1.1 miRNAs Serve as a Tumor Suppressor. 10.4.1.1.1 Let-7 Family. |
| Record Nr. | UNINA-9910568287503321 |
| Gateway East, Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Counseling women with breast cancer [[electronic resource] ] : a guide for professionals / / Merle A. Keitel, Mary Kopala
| Counseling women with breast cancer [[electronic resource] ] : a guide for professionals / / Merle A. Keitel, Mary Kopala |
| Autore | Keitel Merle A |
| Pubbl/distr/stampa | Thousand Oaks, Calif. ; ; London, : SAGE, 2000 |
| Descrizione fisica | 1 online resource (193 p.) |
| Disciplina | 616.99449 |
| Altri autori (Persone) | KopalaMary |
| Collana | Women's mental health and development |
| Soggetto topico |
Breast - Cancer - Patients - Counseling of
Breast - Cancer - Treatment |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-322-41363-0
1-4522-2051-4 1-4522-2111-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Cover; Contents; Series Editor's Introduction; Preface; Acknowledgments; Chapter 1 - Setting the Stage; Chapter 2 - Breast Cancer: What You Need to Know; Chapter 3 - Risk Factors and Prevention; Chapter 4 - The Breast Cancer Experience; Chapter 5 - How to Do a Psychosocial Assessment; Chapter 6 - Intervening with the Individual; Chapter 7 - Group Interventions; Chapter 8 - Family Issues; Chapter 9 - Therapeutic Issues; Appendix A: Resources for Women with Breast Cancer; References; Index; About the Authors |
| Record Nr. | UNINA-9910478875403321 |
Keitel Merle A
|
||
| Thousand Oaks, Calif. ; ; London, : SAGE, 2000 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug and therapy development for triple negative breast cancer / / edited by Pravin Kendrekar, Vinayak Adimule, and Tara Hurst
| Drug and therapy development for triple negative breast cancer / / edited by Pravin Kendrekar, Vinayak Adimule, and Tara Hurst |
| Pubbl/distr/stampa | Weinheim, Germany : , : WILEY-VCH GmbH, , [2023] |
| Descrizione fisica | 1 online resource (323 pages) |
| Disciplina | 016.22 |
| Soggetto topico | Breast - Cancer - Treatment |
| ISBN |
3-527-84116-4
3-527-84118-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Title Page -- Contents -- Preface -- Part I History of Breast Cancer -- 1 Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches -- 1.1 Introduction -- 1.2 Imaging Techniques -- 1.2.1 Mammography (MG) -- 1.2.2 Ultrasonography (US) -- 1.2.3 Magnetic Resonance Imaging (MRI) -- 1.3 Microwave Breast Imaging Methods -- 1.3.1 Microwave Tomography -- 1.3.2 Radio-Based Microwave Imaging -- 1.4 Biomarkers and Biosensors for Breast Cancer Detection -- 1.4.1 Biomarkers -- 1.4.2 Biosensors -- 1.5 Conclusion -- Acknowledgment -- Conflict of Interest -- Authors Contribution -- References -- 2 DNA Replication Stress and Genome Instability in Breast Cancer -- 2.1 Introduction -- 2.2 Causes of Replication Stress and Genomic Instability -- 2.2.1 Replication Dysfunction -- 2.2.2 Transcription-Induced Stress -- 2.2.3 Genomic Aberrations and Instability -- 2.3 Molecular Mechanism of Genomic Instability -- 2.3.1 Problems Faced During DNA Damage Repair -- 2.3.2 Transcriptional Stress -- 2.3.3 CIN: Result of Defective Mitosis -- 2.4 Aftermath of Replication Stress on Cell and Its Fate -- 2.4.1 Conservation of Stalled Replication Forks -- 2.4.2 Chromosome Segregation Defect Check by HR Repair -- 2.4.3 Aging, Cell Death, and Senescence -- 2.5 Therapeutic Approach -- 2.6 Conclusion -- Abbreviations -- References -- 3 Recent Advancement of Nanotherapeutics to Treat Breast Cancer -- 3.1 Introduction -- 3.2 Pathophysiology of Breast Cancer -- 3.3 Classification of Breast Cancer -- 3.4 Techniques for Breast Cancer Detection -- 3.5 Current Breast Cancer Therapies -- 3.6 Nanotherapeutics for Breast Cancer Treatment and Metastasis -- 3.6.1 Nanodiamonds (NDs) -- 3.6.2 Intrinsic Toxicity Reduction -- 3.6.3 Diminishing Chemoresistance (CR) -- 3.6.4 Delivery of Combination Therapeutics Through NDs -- 3.7 Polymer-Based Nanoparticles (PBNPs).
3.8 Inorganic Nanoparticles (IONPs) -- 3.9 Hydrogels (HGLs) and Microbubbles (MBs) -- 3.10 Recent Patents of Nanotherapeutics for Breast Cancer Treatment -- 3.11 Clinical Trials of Nanotherapeutics for Breast Cancer -- 3.12 Conclusion and Future Perspectives -- References -- 4 HER Receptor in Breast Cancer -- 4.1 Introduction -- 4.2 Role of HER Receptors in the Human Body -- 4.3 HER2 Receptor in Breast Cancer Progression -- 4.4 Conclusion -- Conflict of Interest -- References -- 5 Human Endogenous Retroviruses in Triple-Negative Breast Cancer -- 5.1 Introduction -- 5.2 HERVs in Breast Cancer and TNBC -- 5.3 TROJAN lncRNA and TNBC -- 5.4 HERVs and Breast Cancer Treatments -- 5.5 Conclusion -- 5.6 Search Strategy -- References -- Part II Novel Drug Discovery and Development -- 6 Development in Drug Repurposing for the Treatment of Acute Leukemia Complicating Metastatic Breast Cancer -- 6.1 Introduction -- 6.1.1 Acute Leukemia's -- 6.1.2 Mitochondrial cAMP-PKA Signaling -- 6.1.3 Nuclear Compartment -- 6.1.4 Cytosolic Compartment and Plasma Membrane -- 6.2 Conclusion -- Conflict of Interest -- References -- 7 Novel Pharmaceutical Nanomaterials to Advance the Current Breast Cancer Treatment - Current Trends and Future Perspective -- 7.1 Introduction -- 7.2 Graphene-Based Nanomaterials for Breast Cancer -- 7.3 Light-Based Nanotechnology for Breast Cancer -- 7.3.1 Photodynamic Therapeutic Nanomaterials -- 7.3.2 Photothermal Therapeutic Nanomaterials -- 7.4 Green Synthesis of Gold Nanoparticles for Breast Cancer -- 7.5 Nanocarriers for Gene Therapy and Immunotherapy -- 7.6 Conclusion and Recommendations -- References -- Part III Advanced Technologies in Breast Cancer Therapy -- 8 Artificial Intelligence-Driven Decisions in Breast Cancer Diagnosis -- 8.1 Introduction -- 8.2 Breast Cancer -- 8.3 Diagnosis of Breast Cancer -- 8.4 Artificial Intelligence. 8.4.1 Artificial Intelligence and Medical Imaging -- 8.5 Conclusion -- 8.6 Future Challenges -- References -- 9 Establishing Nanotechnology-Based Drug Development for Triple-Negative Breast Cancer Treatment -- 9.1 Introduction -- 9.2 Triple-Negative Breast Cancer -- 9.2.1 Molecular Mechanisms (Signaling Pathways) Involved in TNBC Therapeutics -- 9.2.2 Conventional Therapeutics -- 9.2.3 Promising Nanotechnology Innovations for TNBC Therapy -- 9.2.4 Vaccines Under the Clinical Trial (CT) for TNBC Treatment -- 9.2.5 USFDA-Approved Clinical Trials -- 9.2.6 Current Status of TNBC Treatment -- 9.2.7 Recent Patents Based on Nanoformulations for TNBC Treatment -- 9.3 Challenges -- 9.4 Future Perspectives on TNBC Metastasis Therapy -- 9.4.1 NEO Adjuvant Modeling -- 9.4.2 Execution of In Vivo Genetic Screening -- 9.4.3 Identification of Effective Drugs for TNBC -- 9.4.4 Synergistic Effect of Drugs that Almost Eliminate Tumor -- 9.5 Conclusion -- References -- 10 Etiology and Therapy of Hormone Receptor-Positive Breast Cancer -- 10.1 Introduction -- 10.2 Etiology -- 10.2.1 Role of Estrogen Hormone -- 10.2.2 Role of Progesterone Hormone -- 10.2.3 Estrogen Receptor (ER) -- 10.2.4 Progesterone Receptor (PR) -- 10.3 Human Epidermal Growth Factor-2 (HER-2) -- 10.4 Various Types of Breast Cancer Detected Under Hormone Receptor Breast Cancer -- 10.4.1 Estrogen Receptor (ER) Positive -- 10.4.2 Progesterone Receptor (PR) Positive -- 10.4.3 Hormone Receptor (HR) Negative -- 10.5 Detection -- 10.6 Therapy -- 10.6.1 Selective Estrogen-Receptor Response Modulators (SERMs) -- 10.6.2 Aromatase Inhibitors -- 10.6.3 Estrogen-Receptor Down Regulators (ERDs) -- 10.6.4 Luteinizing Hormone-Releasing Hormone Agents (LHRH) -- 10.7 Limitations of Hormone Therapy -- 10.7.1 Tamoxifen -- 10.7.2 Raloxifene -- 10.7.3 Aromatase Inhibitors -- 10.7.4 Fulvestrant. 10.8 Triple-Negative Breast Cancer -- 10.8.1 Clinical History of Triple-Negative Breast Cancer -- 10.8.2 Imaging Characteristics/Features of Triple-Negative Breast Cancer -- 10.8.3 Subtypes of TNBC -- 10.8.4 Treatment of Triple-Negative Breast Cancer -- 10.8.5 Advance TNBC -- 10.8.6 Pharmacogenomics -- 10.9 Conclusion -- References -- 11 Donor-Acceptor-Based Heterocyclic Compounds as Chemotherapy and Photothermal Agents in Treatment of Breast Cancer Cell -- 11.1 Introduction -- 11.2 Causes for Breast Cancer -- 11.3 Imaging and Screening of Breast Cancer -- 11.4 Photothermal Therapy (PTT) -- 11.5 Acceptor-Donor-Based Heterocyclic Compounds -- 11.6 Examples of Organic-Based Donor-Acceptor -- 11.6.1 Indocyanine -- 11.7 Polymers-Based Agents -- 11.7.1 Phthalocyanine -- 11.8 Conclusion -- References -- Part IV Regulatory, Clinical Aspects and Case Studies -- 12 An Insight into Drug Regulatory Affairs and the Procedures -- 12.1 Endpoints of Clinical Trials for the Approval of Cancer Drugs and Biologics -- 12.2 Statutory and Regulatory Requirements for Effectiveness -- 12.2.1 Endpoints Supporting Previous Oncology Approvals -- 12.2.2 Endpoints Based on Tumor Assessments -- 12.2.3 Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer -- 12.2.4 Cancer Drug and Diagnostic Regulation by the FDA -- 12.2.5 Considerations for Clinical Trial Design and Analysis -- 12.2.6 Single-Arm Studies -- 12.2.7 Randomized Studies Designed to Demonstrate Noninferiority -- 12.3 Clinical Trial Design Considerations -- 12.4 Clinical Trial Analysis Issues -- 12.5 Use of Pathological Complete Response as an Endpoint to Support Accelerated Approval in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer -- 12.6 Developing Treatments for Premenopausal Women with Breast Cancer -- 12.7 Recommendations by FDA. 12.7.1 Access to Experimental Cancer Drugs -- 12.7.2 How to Get a Hold of an Experimental Drug -- 12.7.3 Access to More Information (Compassionate Use) -- 12.8 What is Right to Try? -- 12.9 Examples of Drugs Approved for Breast Cancer -- References -- 13 A Comprehensive Review of Some Heat-Shock Proteins in the Development and Progression of Human Breast Cancer -- 13.1 Introduction -- 13.1.1 Cancer and Its Economic Burden on Human -- 13.2 Structure-Functional Features of HSPs -- 13.2.1 Heat-Shock Protein 40 -- 13.2.2 Heat-Shock Protein 60 -- 13.2.3 Heat-Shock Protein 70 -- 13.2.4 Heat-Shock Protein 90 -- 13.3 Conclusion and Future Perspectives -- Acknowledgments -- References -- 14 Nanoparticle-Based Therapeutics for Triple Negative Breast Cancer -- 14.1 Breast Cancer: State of Research and Practice -- 14.2 Triple Negative Breast Cancer (TNBC) and Treatment Approaches -- 14.3 Nanoparticle Therapeutics for TNBC -- 14.3.1 Metallic Nanoparticles -- 14.3.2 Dendrimers -- 14.3.3 Lipid-Based Nanoparticles (LNPs) -- 14.3.4 CRISPR Nanoparticles -- 14.3.5 Exosomes (Exo) -- 14.3.6 Nucleic Acid (NA)-Based Therapeutics -- 14.4 Ligands Used to Enhance Nanoparticle Therapeutics in TNBC -- 14.4.1 Antibodies -- 14.4.2 Peptides -- 14.4.3 Aptamers -- 14.4.4 Small Molecules -- 14.5 Conclusion -- References -- 15 Current Updates in Breast Cancer Drugs -- 15.1 Introduction -- 15.2 Therapeutic Approaches -- 15.2.1 Hormonotherapy -- 15.2.2 Chemotherapy -- 15.3 Targeted Therapy -- 15.3.1 Drug Repurposing -- 15.3.2 HER2 Inhibitors -- 15.3.3 PARP Inhibitors -- 15.3.4 Immunotherapy -- 15.3.5 Others Novel Targets -- 15.4 Conclusion -- Acknowledgment -- Conflict of Interest -- Authors Contribution -- References -- Index -- EULA. |
| Record Nr. | UNINA-9910831190103321 |
| Weinheim, Germany : , : WILEY-VCH GmbH, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Four methods of treating breast cancer [[electronic resource]]
| Four methods of treating breast cancer [[electronic resource]] |
| Pubbl/distr/stampa | [Bethesda, Md.] : , : National Institutes of Health, , [between 2000 and 2009?] |
| Soggetto topico | Breast - Cancer - Treatment |
| Soggetto genere / forma |
Documentary films.
Streaming videos. |
| Formato | Videoregistrazioni  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910699197203321 |
| [Bethesda, Md.] : , : National Institutes of Health, , [between 2000 and 2009?] | ||
| Videoregistrazioni | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The future of prevention and treatment of breast cancer / / Jose Russo
| The future of prevention and treatment of breast cancer / / Jose Russo |
| Autore | Russo Jose <1942-> |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (195 pages) |
| Disciplina | 616.99449 |
| Soggetto topico |
Breast - Cancer - Prevention
Breast - Cancer - Treatment Càncer de mama Medicina preventiva Terapèutica |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-72815-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495210303321 |
|
Russo Jose <1942->
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
A health reporter faces breast cancer [[electronic resource]]
| A health reporter faces breast cancer [[electronic resource]] |
| Pubbl/distr/stampa | [Bethesda, Md.] : , : National Institutes of Health, , [between 2000 and 2009?] |
| Altri autori (Persone) |
BrodyJane E
PressmanPeter I |
| Soggetto topico |
Breast - Cancer - Patients - United States
Breast - Cancer - Treatment |
| Soggetto genere / forma |
Documentary films.
Streaming videos. |
| Formato | Videoregistrazioni |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910699197003321 |
| [Bethesda, Md.] : , : National Institutes of Health, , [between 2000 and 2009?] | ||
| Videoregistrazioni | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
HER2-positive breast cancer / / Sara Hurvitz, Kelly McCann
| HER2-positive breast cancer / / Sara Hurvitz, Kelly McCann |
| Autore | Hurvitz Sara |
| Pubbl/distr/stampa | St. Louis, Missouri : , : Elsevier, , [2019] |
| Descrizione fisica | 1 online resource (265 pages) |
| Disciplina | 616.9944906 |
| Soggetto topico | Breast - Cancer - Treatment |
| ISBN | 0-323-58123-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910583320603321 |
|
Hurvitz Sara
|
||
| St. Louis, Missouri : , : Elsevier, , [2019] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hereditary gastric and breast cancer syndrome : CDH1 / / Giovanni Corso, Paolo Veronesi, and Franco Roviello, editors
| Hereditary gastric and breast cancer syndrome : CDH1 / / Giovanni Corso, Paolo Veronesi, and Franco Roviello, editors |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer Nature Switzerland AG, , [2023] |
| Descrizione fisica | 1 online resource (412 pages) |
| Disciplina | 616.994330426 |
| Soggetto topico |
Breast - Cancer - Genetic aspects
Breast - Cancer - Treatment Stomach - Cancer - Genetic aspects |
| ISBN | 3-031-21317-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I. Epidemiology -- Family History and the Risk of Breast and Gastric Cancer -- Worldwide CDH1 Germline Mutation Frequency and the Transhormesis Hypothesis -- Hereditary Lobular Breast Cancer: A Newly Defined Syndrome -- Part II. Genetics -- Genetic Counseling and Prevention in Families at High Risk for HDGC and Other Hereditary Syndromes -- CTNNA1, a New HDGC Gene: Inactivating Mechanisms and Driven Phenotypes -- Revisiting the Biological and Clinical Impact of CDH1 Missense Variants -- Other Syndromes and Genes Associated with Gastric Cancer Predisposition -- Computer-Assisted Interpretation of Cancer-Predisposing Variants -- Part III. Pathology -- Histopathology of Hereditary Diffuse Gastric Cancer: From Grossing and 3D Microscopy to Immunophenotypic and Molecular Profiling -- HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations -- Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers -- Part IV. Endoscopy and Imaging -- Endoscopy: Is there Anything New? -- Endoscopic Surveillance and Pathology of Biopsies in CDH1, CTNNA1 and HDGC-Like Families -- Lobular Carcinoma of the Breast: Spectrum of Imaging Findings and New Emerging Technologies on the Horizon -- Part V. Surgery -- Prophylactic Total Gastrectomy: Techniques -- Prophylactic Total Gastrectomy: How Many? -- Hereditary Lobular Breast Cancer Syndrome: Role of Surgery -- Breast Reconstruction -- Part VI. New Issues -- Psychological Burden and Preferences in CDH1 Mutation Carriers: Beyond the Cancer Diagnosis -- Drug Repurposing in Gastric Cancer: Current Status and Future Perspectives -- The Chemoprevention of Hereditary Diffuse Gastric Cancer -- Malformations and Malformative Syndromes Associated with CDH1 -- Hereditary Breast Cancer Non-CDH1 Associated -- Part VII. Patient Advocacy -- My Hereditary Gastric Cancer -- Hereditary Breast Cancer Syndrome, My Experience -- Part VIII. Miscellaneous -- β-Hemoglobinopathies and Early Onset of Cancers in Adulthood. Epidemiology in Southeastern Asia & Brunei with Emphasis for Prevention and Treatment. |
| Record Nr. | UNINA-9910682567703321 |
| Cham, Switzerland : , : Springer Nature Switzerland AG, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
